Heart failure & cardiomyopathiesRandomised controlled trial
Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial
- Randomised controlled trial (rationale and design)
- investigator-initiated
- prospective
- open-label
- multicentre
- strategy trial
- 2:1 randomisation
- hierarchical testing
- Follow-up 3 years
29 sites; mean of 176 tricuspid transcatheter edge-to-edge repair (T-TEER) patients in 4.5 years before activation · Safety outcome: Transcatheter tricuspid valve interventions (TTVI) complications, life-threatening bleeding and death
Authors' conclusion
The TRIC-I-HF-DZHK24 trial will define the role of TTVI in patients with severe TR and right-sided HF.
Study context
- Population
- Severe tricuspid regurgitation (TR) with manifest right-sided heart failure (HF) and increased risk for HF hospitalisation (HF hospitalizations (HFH) in previous year, cardio-renal syndrome or cardio-hepatic syndrome)approximately 360 planned
- Comparison
- TTVI + optimal medical therapy (OMT) vs OMT alone
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial. Eur J Heart Fail. Published 11 August 2025. doi:10.1002/ejhf.3795
Summarised from the published abstract; every number is checked against it